Alexander Treiber
Overview
Explore the profile of Alexander Treiber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steiner M, Botticelli L, Bergamini G, Micioni Di Bonaventura E, Gatfield J, Williams J, et al.
Int J Eat Disord
. 2024 Mar;
57(7):1418-1432.
PMID: 38456603
Objective: Test the efficacy of the selective orexin 1 receptor (OX1R) antagonist (SO1RA) nivasorexant in an animal model of binge-eating disorder (BED) and study its dose-response relationship considering free brain...
2.
Treiber A, Seeland S, Segrestaa J, Lescop C, Bolli M
Xenobiotica
. 2024 Feb;
54(4):182-194.
PMID: 38400854
1. Ponesimod is a selective modulator of the sphingosine 1-phosphate receptor 1 (S1P) approved for the treatment of active relapsing forms of multiple sclerosis. The chemical structure of ponesimod contains...
3.
Treiber A, Seeland S, Haschimi B, Weigel A, Williams J, Gabillet J
Xenobiotica
. 2024 Feb;
54(3):124-137.
PMID: 38358311
Nivasorexant was the first orexin-1 selective receptor antagonist entering clinical development. Despite encouraging preclinical evidence in animal models, a proof-of-concept trial in binge-eating patients recently failed to demonstrate its clinical...
4.
Williams J, Bolli M, Brotschi C, Sifferlen T, Steiner M, Treiber A, et al.
J Med Chem
. 2024 Feb;
67(4):2337-2348.
PMID: 38331429
The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2). Selective OX1 receptor antagonists (SO1RA) are gaining interest for their potential use in...
5.
Brotschi C, Bolli M, Gatfield J, Roch C, Sifferlen T, Treiber A, et al.
RSC Med Chem
. 2024 Jan;
15(1):344-354.
PMID: 38283232
Selective orexin 2 receptor antagonists (2-SORA) such as seltorexant (15) are in clinical development for the treatment of insomnia and other conditions such as depression. Herein, we report our structure-activity-relationship...
6.
Berger B, Kaufmann P, Berse M, Treiber A, Grignaschi N, Dingemanse J
Pharmacol Res Perspect
. 2023 Oct;
11(5):e01143.
PMID: 37800597
Nivasorexant, a selective orexin-1-receptor antagonist, has recently been assessed in the treatment of humans with binge-eating disorder. Herein, the inhibitory potential of nivasorexant on cytochromes P450 (CYPs) 2C9, 2C19, and...
7.
Treiber A, Aissaoui H, Delahaye S, Glutz S, Grimont J, Muller C, et al.
ChemMedChem
. 2023 Mar;
18(10):e202300030.
PMID: 36892179
The dual orexin receptor antagonist daridorexant was approved in 2022 in the USA and EU for the treatment of insomnia. The purpose of this study was the identification of its...
8.
Treiber A, Delahaye S, Weigel A, Aeanismaa P, Gatfield J, Seeland S
Xenobiotica
. 2023 Feb;
53(3):173-183.
PMID: 36809238
Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia disorder and has shown improvement in sleep outcomes and daytime functioning. The present work describes its biotransformation...
9.
Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, et al.
ChemMedChem
. 2020 Sep;
15(23):2286-2305.
PMID: 32937014
Since its discovery in 1998, the orexin system has been of interest to the research community as a potential therapeutic target for the treatment of sleep/wake disorders, stress and anxiety...
10.
Treiber A, Delahaye S, Seeland S, Gnerre C
Pharmacol Res Perspect
. 2020 Jul;
8(4):e00619.
PMID: 32613761
The dual endothelin receptor antagonist macitentan was approved in 2013 for the treatment of pulmonary arterial hypertension. Macitentan is an inducer of cytochrome P450 expression in vivo in animal species...